Insmed Inc.
FDA Grants Priority Review to Insmed's Brensocatib for Bronchiectasis
Summary
On February 6, 2025, Insmed Incorporated announced that the U.S. Food and Drug Administration (FDA) accepted for review the Company's New Drug Application (NDA) for brensocatib, a potential treatment for non-cystic fibrosis bronchiectasis, and granted it priority review with a target action date of August 12, 2025. If approved, brensocatib would be the first and only treatment for bronchiectasis and the first dipeptidyl peptidase 1 (DPP1) inhibitor. The FDA's acceptance is based on data from the Phase 3 ASPEN study, which demonstrated significant reductions in pulmonary exacerbations and lung function decline with brensocatib compared to placebo.
Profitelligence Alerts
Get alerts for INSM
Be first to know when Insmed Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Insmed Inc.
Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.
Official SEC Documents
Advertisement